Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
US12403185B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 22, 2021 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Nov 12, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of using allogeneic cells in therapy by combining allogeneic cell therapy with anti-CD137 antibody drug conjugates (ADCs). Disclosed are methods of treating or preventing a host versus graft (HvG) rejection in a human subject receiving allogeneic cell therapy by administering to the human subject an anti-CD137 ADC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.